JAFRAL Joins Forces in IMMOONITY Project to Advance Sustainable Bovine Immunotherapy

JAFRAL proudly contributed to the international IMMOONITY project, led by FarmPharma AB with partners Karolinska Institutet and Cebiphar, focused on developing sustainable immunotherapy for cattle to reduce antibiotic use and combat antimicrobial resistance (AMR).

Our key contribution was scaling up production of the lead candidate InterferOx from laboratory batches to larger-scale manufacturing, while optimizing processes to improve endotoxin removal and overall yield. This work ensures high-quality material is available for final activity testing and future clinical studies.

The IMMOONITY project successfully identified promising components for a novel bovine immunotherapy and developed a reliable in vivo model of mycoplasma-induced pneumonia in calves, providing a robust platform for efficacy studies. Through strong collaboration among all partners, the project has advanced sustainable solutions that strengthen natural defenses in livestock and reduce reliance on antibiotics.

JAFRAL continues to drive innovation in biotechnology and sustainable veterinary solutions, with potential applications for other animals.

‍